Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.61 |
| ▸ | CREBBP | Q92793 | 13/20 | 0.61 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1347920 | 0.81 | CREBBP (0.61) | BRD4CREBBPCRBNEP300 | |
| SCHEMBL14721601 | 0.79 | CA9 (0.40) | BRD4CREBBPCRBNCA9CYP19A1 | |
| SCHEMBL1347231 | 0.76 | CREBBP (1.00) | BRD4CREBBPCRBNEP300AHR | |
| SCHEMBL1347469 | 0.76 | BRD4 (0.55) | BRD4CREBBP | |
| SCHEMBL22660 | 0.75 | AHR (0.61) | CA9GRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL17479629 | 0.75 | CA9 (0.44) | BRD4CREBBPCA9CYP19A1EP300 | |
| Hydrochloric Acid SCHEMBL15206761 | 0.74 | AHR (0.59) | CA9GRIA1CACNG8PDE3BPDE3A | |
| Bromide SCHEMBL9824774 | 0.74 | AHR (0.59) | CA9GRIA1CACNG8PDE3BPDE3A | |
| SCHEMBL736368 | 0.74 | CA9 (0.73) | BRD4CRBNCA9PDE3BPDE3A | |
| SCHEMBL18496459 | 0.73 | ALDH1A1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063040-B2 | Triazabenzo[E]azulene derivatives for the treatment of tumors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-11-22 | — | — | US | disclosed |
| EP-2111403-B1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | MERCK PATENT GESELLSCHAFT (DE) | 2010-03-11 | — | — | US | disclosed |
| EP-2111403-A1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | Merck Patent GmbH (DE) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008052628-A1 | TRIAZABENZO[E]AZULENE DERIVATIVES FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063028-A1 | Triazabenzo[E]Azulene Derivatives for the Treatment Of Tumors | TGFBR1, TGFBR2, ACVR1 | BRD4 2601/4885CREBBP 2735/4885CRBN 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.